Novo Nordisk, the Danish pharmaceutical giant best known for its GLP-1 therapies, has announced a significant strategic partnership with Anthropic to integrate Claude AI models into its drug discovery and research workflows.
The collaboration, announced September 16, will begin with Claude Science—a variant optimized for scientific reasoning—and focus on specific R&D workflows. The goal is to accelerate the notoriously slow and expensive process of bringing new medicines to market.
“AI has the potential to supercharge our R&D organisation,” said CEO Mike Doustdar in a statement. “This partnership represents our commitment to staying at the forefront of technological innovation in pharmaceutical development.”
Anthropic CEO Dario Amodei framed the deal as part of a broader vision: “Frontier AI could help compress a century’s worth of biological and medical breakthroughs into a decade.”
The partnership builds on Novo Nordisk’s existing AI initiatives. The company previously announced collaborations with OpenAI and AWS, but this marks its first direct engagement with Anthropic. Industry analysts see the choice of Claude as strategic—Anthropic’s models have gained recognition for strong scientific and reasoning capabilities.
For Anthropic, the deal represents another victory in its enterprise expansion strategy. The company has been aggressively pursuing partnerships across healthcare, finance, and technology sectors, positioning Claude as the preferred AI for complex knowledge work.
The timing is notable. The pharmaceutical industry faces mounting pressure to accelerate drug development while managing costs. A successful AI partnership could serve as a template for the sector, potentially triggering similar announcements from competitors.
Financial terms of the deal were not disclosed, but the partnership is expected to deploy across multiple R&D teams over the coming quarters. Initial results will focus on target identification and molecular optimization—areas where AI has shown particular promise.